Novo Nordisk Announces Price Cuts for Ozempic and Wegovy, Expanding Access to Weight Loss Medications
Novo Nordisk is making significant strides in lowering the financial barrier to entry for its popular GLP-1 medications, Ozempic and Wegovy, offering new discounts for patients paying out of pocket. The move comes as demand for these drugs – initially developed for diabetes management but increasingly used for weight loss and other health benefits – continues to surge across the United States.
The pharmaceutical company announced that, through the end of March, individuals with valid prescriptions can purchase the 0.25 mg and 0.5 mg doses of Ozempic and all doses of Wegovy for $199 per month for a period of two months. Following this introductory period, the monthly cost will increase to $349. These savings are accessible through the drugs’ official websites and can be utilized at participating pharmacies and telehealth providers. Notably, the 2 mg dose of Ozempic is excluded from this discount program.
“The U.S. health care system is complex, with different types of insurance and various ways for patients to obtain their medicines,” a senior company official stated. “Our new savings offers provide immediate impact, bringing forward greater cost savings for those who are currently without coverage or choose to self-pay.”
Currently, the list price for both Ozempic and Wegovy remains above $1,000 per month, making them inaccessible to many. This announcement follows a recent partnership between Novo Nordisk and Costco, which began offering lower doses of Ozempic and Wegovy at $499 per month for cash-paying customers. Additional cash-pay options are also available through CVS, Walmart, and Novo Nordisk’s direct-to-consumer website. Furthermore, former President Donald Trump recently indicated he is collaborating with Novo Nordisk and Eli Lilly to potentially reduce out-of-pocket costs even further, aiming for a range of $50 to $350 depending on dosage and insurance coverage.
Expanding Applications Drive Demand
The growing popularity of GLP-1 medications is fueled by research demonstrating benefits beyond weight loss. Studies suggest these drugs may also improve heart health, aid in the treatment of sleep apnea, and even reduce cancer mortality. A recent survey conducted by the KFF found that nearly one in five U.S. adults has tried a GLP-1 drug, with one in eight currently using one. Approximately 25% of current users report having insurance but still being responsible for the full cost of the medication.
Dr. Shauna Levy, medical director of the Tulane Weight Loss Center in New Orleans, believes the new pricing structure will significantly improve access to treatment. “Less than a quarter of the country has the commercial insurance that actually covers GLP-1s,” Dr. Levy explained. “If $500 per month is too expensive, then there’s going to be a new category of patients that $350 a month is more affordable.”
Potential Downsides and Employer Coverage Concerns
Despite the positive outlook, experts caution that the discounts may not be without drawbacks. One health policy professor at Vanderbilt University Medical Center in Nashville, Tennessee, warned that the $199 introductory rate could be a “teaser,” potentially leading patients to discontinue treatment when the price increases to $349 before experiencing substantial benefits. “It’s a smart sales strategy, but I’m not sure it’s a very good strategy for thinking about the health of people who are interested in taking these drugs and who could benefit from them,” the professor noted.
Lower cash prices could also prompt employers to reconsider their coverage policies. While more companies are beginning to cover GLP-1 drugs compared to last year, rising benefit costs may incentivize some to view these cash-pay options as justification for reducing their benefits packages. “If they’re looking for places to cut, having a lot of focus and attention on these lower-cost cash-pay options could give employers an excuse,” the professor added.
Dr. Levy emphasized that GLP-1 medications represent just one component of obesity treatment, highlighting bariatric surgery – often fully covered by insurance – as a viable option for many individuals.
Ultimately, Dr. Levy believes the price reductions represent a significant win for patients. “Driving the price down increases access,” she stated.
Cleveland Clinic provides further information on how weight loss medications work.
© 2025 HealthDay. All rights reserved.
Citation: Novo Nordisk rolls out lower prices for Ozempic and Wegovy (2025, November 19) retrieved 19 November 2025 from https://medicalxpress.com/news/2025-11-novo-nordisk-prices-ozempic-wegovy.html. This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
